Indian Investors Turn Cautious On Compliance Concerns
This article was originally published in PharmAsia News
Executive Summary
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.